Improved
6112 HealthChanged
3785 LivesSaved
3568 Lives0 lives impacted in the last 24 hrs Learn More
ArtFotoDima/Fotolia
FDA approval of Addyi (flibanserin), or the “little pink pill,” was big news last year. It was applauded by some women’s groups as, finally, a first step toward addressing sexual dysfunction in women.
The FDA passed the drug by an 18-6 vote, after four clinical trials of 3099, mostly white, women for treatment of hypoactive sexual desire disorder, or HSDD. The women tested were aged 18-56 years old.
“Those who took flibanserin reported a modest but measurable rise in sexual desire and increased their number of 'sexually satisfying encounters' by roughly one per month,” wrote the Los Angeles Times.
Now one year later, a new study by Netherlands researchers shows that those results may be overestimated.
Researchers reviewed eight clinical trials, five published and three unpublished, and found that use of Addyi only resulted in one-half additional "satisfying sexual event" per month while at the same time “significantly increasing the risk of dizziness, somnolence, nausea, and fatigue,” according to the study.
Addyi has often been touted as the “female Viagra,” which in some ways has set it up for failure.
Viagra works in men by vasodilating the blood vessels to the penis so it can become engorged with blood to form an erection. The effect is purely mechanical. Viagra is only taken when needed.
Sexual desire in women is far more complicated. Women must first have increased desire and arousal to have sex.
Addyi is intended to work on a women’s biological libido, or her mind, by increasing the activity of the neurochemical serotonin in the brain.
It does not dilate blood vessels in the vagina to create engorgement, though this does occur naturally when a woman is aroused. Increased blood flow to a woman's vagina will not lead to having more sexual encounters for women like it does for men.
And unlike Viagra, Addyi must be taken every day, similar to antidepressants, which is what it was originally targeted to treat. Addyi did not pass FDA approval to be used as an antidepressant, despite two attempts, so was repurposed when it was determined to affect women’s sexual response.
John Randolph, M.D., professor of obstetrics and gynecology at the University of Michigan Health System, told Shape magazine, “that female sexual desire has much less to do with hormones but everything to do with how secure and happy a woman feels in her relationship and in her life.”
Randolph went on to say that many people, both male and female, are more inclined to try and solve their lack of desire by taking a pill instead of exploring emotionally what might be behind their lack of desire.
The search for how to help women with hyposexual desire is still needed, and should not stop with the approval of a drug that really may do little to help. More research on hormone levels, reduction of pain, feeling supported and cared for by their significant others is needed.
The recommendations of the Netherlands researchers is that “before flibanserin can be recommended in guidelines and clinical practice, future studies should include women from diverse populations, particularly women with comorbidities, medication use, and surgical menopause.”
Michele is an R.N. freelance writer with a special interest in woman’s healthcare and quality of care issues.
Edited by Jody Smith
Article Sources
1) As FDA approves 'pink Viagra' for women, controversy persists. Los Angeles Times.com. Retrieved March 31, 2016.
http://www.latimes.com/science/sciencenow/la-sci-sn-fda-female-viagra-flibanserin-20150818-story.html
2) "Female Viagra" Doesn't Work, Says Study. Shape.com. Retrieved March 31, 2016.
http://www.shape.com/lifestyle/sex-and-love/female-viagra-doesnt-work
3) Jaspers, Loes MD. Efficacy and Safety of Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Women. A Systematic Review and Meta-Analysis. JAMA Intern Med. Published online February 29, 2016.
http://archinte.jamanetwork.com/article.aspx?articleid=2497781
Add a CommentComments
There are no comments yet. Be the first one and get the conversation started!